<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623995</url>
  </required_header>
  <id_info>
    <org_study_id>2022-22</org_study_id>
    <nct_id>NCT05623995</nct_id>
  </id_info>
  <brief_title>Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)</brief_title>
  <official_title>Effect of Evolocumab on Chronic Total Occlusions After Successful Percutaneous Coronary Intervention (EVOLO-CTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lin Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin&#xD;
      type-9 (PCSK9) inhibitors added to regular statin therapy on neointimal hyperplasia and&#xD;
      target lesion failure (TLF) in patients with chronic total occlusions (CTOs) undergoing&#xD;
      successful percutaneous coronary intervention (PCI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic total occlusions (CTOs) are found in 15-25% of patients with stable angina pectoris.&#xD;
      The presence of a CTO indicates unfavorable prognosis, with higher rate of major adverse&#xD;
      cardiovascular events. Statins are frequently used after PCI in order to lower LDL&#xD;
      cholesterol levels and reduce the chances of coronary artery obstruction recurring. Despite&#xD;
      this preventive measure, high risk for restenosis and re-occlusion was observed a significant&#xD;
      proportion of patients with CTOs undergoing PCI.&#xD;
&#xD;
      Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors represent a novel class of&#xD;
      lipid-lowering drugs leading to rapid, profound, and consistent reductions in LDL-C levels.&#xD;
      The effect of PCSK9 inhibitor in patients with CTO, after a recent PCI is not known.&#xD;
&#xD;
      In this study the investigators want to evaluate the effect of the PCSK9 inhibitor on&#xD;
      neointimal hyperplasia and target lesion failure (TLF) in patients with CTOs receiving&#xD;
      regular statin treatment. A serial of intravascular ultrasound imaging study will be&#xD;
      performed to determine the restenosis at 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neointimal volume with intravascular ultrasound (IVUS) (mm3 per 1mm)</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of neointima volume by IVUS between PCSK9 inhibitors group and control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>TLF is defined as a composite of: all cardiac death, target vessel myocardial infarction (SCAI definition), and clinically driven target lesion revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in angina status assessed with the Seattle Angina Questionnaire</measure>
    <time_frame>3,12 months</time_frame>
    <description>5 Seattle Angina Questionnaire subscales (0-100), higher scores indicating better angina status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia</measure>
    <time_frame>3,12 months</time_frame>
    <description>Ischemic burden assessed with CMR from baseline to 3 and 12 months follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular systolic function assessed with CMR</measure>
    <time_frame>3,12 months</time_frame>
    <description>The left ventricular ejection fraction assessed with CMR from baseline to 3 and 12 months follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>In-stent Restenosis</condition>
  <condition>Major Adverse Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PCSK9 inhibitors added to guideline recommended statin therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will continue to taking guideline recommended statin therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCSK9 inhibitor</intervention_name>
    <description>Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Evolocumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Guideline recommended statin therapy.</description>
    <arm_group_label>Control arm</arm_group_label>
    <other_name>Hydroxymethylglutaryl-Coenzyme A Reductase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age with written informed consent&#xD;
&#xD;
          -  Presence of a CTO in native coronary artery.&#xD;
&#xD;
          -  Stable angina or myocardial ischemia in a territory supplied by CTO&#xD;
&#xD;
          -  CTO located in segments 1-3 (RCA), 6-7 (LAD), 11-12 (LCx)&#xD;
&#xD;
          -  Target artery ≥2.5mm&#xD;
&#xD;
          -  Scheduled to undergo percutaneous coronary intervention (PCI)&#xD;
&#xD;
          -  LDL-C ≥70 mg/dL (≥1.8 mmol/L) in patients who have been on any stable statin regimen&#xD;
             for ≥ 4 weeks prior to enrollment; or LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who&#xD;
             are statin-naïve or have not been receiving stable statin regimen for ≥ 4 weeks prior&#xD;
             to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction within 1 month&#xD;
&#xD;
          -  Known severe chronic kidney disease (estimated Glomerular Filtration Rate [eGFR] &lt;60&#xD;
             mL/min/1.73m2 or serum creatinine level &gt;2.5 mg/dL);&#xD;
&#xD;
          -  History of allergy to iodine contrast agents&#xD;
&#xD;
          -  Allergy to PCSK9 inhibitors or any other ingredients contained in study drug&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Persistent or permanent atrial fibrillation&#xD;
&#xD;
          -  Patients with history of coronary artery bypass graft&#xD;
&#xD;
          -  Inability or unwilling to provide informed consent&#xD;
&#xD;
          -  Malignant neoplasms or Major illness with life expectancy &lt;1 year&#xD;
&#xD;
          -  Planned coronary revascularization or major non-cardiac surgery 12 months after&#xD;
             intervention&#xD;
&#xD;
          -  Patients previously treated with PCSK9 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Wang, MD</last_name>
    <phone>+8615311765609</phone>
    <email>huaianwangxu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Wang, MD</last_name>
      <phone>+86 15311765609</phone>
      <email>huaianwangxu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Lin Zhao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic total occlusion</keyword>
  <keyword>Restenosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

